G
NASA’s Technology Transfer Program solicits inquiries from companies interested in obtaining license rights to commercialize, manufacture and market the following technology. License rights may be issued on an exclusive or nonexclusive basis and may include specific fields of use. NASA provides no funding in conjunction with these potential licenses.
THE TECHNOLOGY:
Innovators at NASA Johnson Space Center have developed a technology that yields three-dimensional (3D) tissue-like assemblies (TLAs) of human broncho-epithelial (HBE) cells for in vitro research on infection of humans by respiratory viruses. Compared to traditional two-dimensional (2D) monolayer cell culture, the 3D TLAs more accurately represent the active environment present in respiratory infections. It offers a cost-effective platform that functions like in vivo human tissue, reducing the need for human subject testing and supporting a more controlled testing environment free from immune system limitations. 3D TLAs provide an opportunity to study the tolerance to bioactive ingredients, the impacts of developing vaccinations on respiratory tissues, and other applications directed to product development for the cosmetics and textile industries.
To express interest in this opportunity, please submit a license application through NASA’s Automated Technology Licensing Application System (ATLAS) by visiting https://technology.nasa.gov/patent/MSC-TOPS-94
If you have any questions, please e-mail NASA’s Technology Transfer Program at [email protected] with the title of this Technology Transfer Opportunity as listed in this SAM.gov notice and your preferred contact information. For more information about licensing other NASA-developed technologies, please visit the NASA Technology Transfer Portal at https://technology.nasa.gov/
These responses are provided to members of NASA’s Technology Transfer Program for the purpose of promoting public awareness of NASA-developed technology products, and conducting preliminary market research to determine public interest in and potential for future licensing opportunities. No follow-on procurement is expected to result from responses to this Notice.